Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 04 2021 - 8:00AM
Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage
company developing precision oncology therapeutics, today announced
it will be presenting three posters highlighting its oral mouse
double minute 2 (MDM2) inhibitor, milademetan, and the importance
of MDM2 as a therapeutic target at the 2021 AACR-NCI-EORTC Virtual
International Conference on Molecular Targets and Cancer
Therapeutics being held October 7-10, 2021.
Additional presentation details can be found below:
Title: MDM2 gene amplification as a predictive
biomarker for the MDM2 inhibitor
milademetanPresenter: Vijaya Tirunagaru, Ph.D.,
Sr. Vice President and Head of Research, Rain Therapeutics, Newark,
CA Presentation Number: P210Date:
October 7, 2021
Title: Milademetan is a potent, murine double
minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT)
Merkel cell carcinoma (MCC) cell linesPresenter:
Varsha Ananthapadmanabhan, Ph.D., Post-Doctoral Fellow, Dana Farber
Cancer Institute, Brigham and Women's Hospital and Harvard Medical
School., Boston, MAPresentation Number:
P203Date: October 7, 2021
Title: The MDM2 inhibitor milademetan induces
synthetic lethality in GATA3 mutant, ER positive breast
cancerPresenter: Vijaya Tirunagaru, Ph.D., Sr.
Vice President and Head of Research, Rain Therapeutics, Newark,
CAPresentation Number: P215Date:
October 7, 2021
Copies of each poster will be available by visiting the "Events
& Presentations" section of the Rain website.
Investor WebinarRain will host an R&D day
webinar on Tuesday, November 9, 2021, at 11:00 am ET featuring
members of Rain’s management team and several key opinion leaders
to discuss Rain’s research and development program, as well as
select clinical and preclinical data in more detail.Interested
parties can register for the webinar here.
About Rain Therapeutics Inc.Rain Therapeutics
Inc. is a late-stage precision oncology company developing
therapies that target oncogenic drivers for which it is able to
genetically select patients it believes will most likely benefit.
This approach includes using a tumor-agnostic strategy to select
patients based on their tumors’ underlying genetics rather than
histology. Rain’s lead product candidate, milademetan, is a small
molecule, oral inhibitor of MDM2, which is oncogenic in numerous
cancers. In addition to milademetan, Rain is also developing a
preclinical program that is focused on inducing synthetic lethality
in cancer cells by inhibiting RAD52.
Media ContactJordyn TemperatoLifeSci
Communications+1.646.876.5196jtemperato@lifescicomms.com
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Apr 2023 to Apr 2024